Reboxetine for Sleep Apnoea After ENT Surgery

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorFlinders University

About this trial

This pilot study will establish the feasibility of a larger trial to investigate whether reboxetine, a medication used to treat depression, can reduce the severity of obstructive sleep apnea (OSA) including increased blood oxygenation in post-surgical OSA patients where positive airway pressure (CPAP) therapy is either frequently poorly tolerated or not an option immediately post surgery. In this randomized, placebo-controlled, double-blind study, participants will use at-home sleep monitoring equipment before and after surgery plus measures of oxygenation. They will be prescribed either reboxetine or a placebo for seven days after surgery and complete questionnaires at the beginning and end of the study.

Eligibility criteria

Qualifiers

Age >18 years

Undergoing elective upper airway surgery

History of obstructive sleep apnoea (OSA)

Disqualifiers

Clinically significant cardiac disease (e.g., arrhythmia, coronary artery disease, or cardiac failure)

History of clinically significant urinary retention, bladder outlet obstruction, or benign prostatic hyperplasia

Poorly controlled hypertension

Epilepsy

Trial design

Treatments tested in this trial

  • Reboxetine 4 MG Oral Tablet
  • Placebo

Treatment groups

20 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Flinders University

Lead sponsor

Flinders Medical Centre

Collaborator